FindTrial
Sign In

To assess effectiveness of a drug dexamethasone to increase pain free period in upper limb surgeries

A comparative study to assess the Efficacy of dexamethasone as an additive to 0.75% ropivacaine versus 0.75% ropivacaine alone on prolongation of duration of analgesia in ultrasound-guided single shot Supraclavicular brachial plexus block for upper limb surgeries.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/04/018390
Enrollment
60
Registered
2019-04-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S598- Other specified injuries of elbowand forearm

Interventions

Intervention1: 8 mg Dexamethasone added to 28ml of 0.75% ropivacaine in single shot Supraclavicular brachial plexus block: 8mg of Dexamethasone added to 28 ml of 0.75% ropivacaine in single shot Supra

Sponsors

Santokba Durlabhji memorial hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients in the age group of 18-60 years of age. 2.Having ASA [American Society of Anaesthesiologists] grade I & II. 3.Patient who gives informed written consent to be included in the study 4.Patients scheduled for elective upper limb surgeries under supraclavicular brachial plexus block.

Exclusion criteria

Exclusion criteria: 1.Age less than 18 years 2.Having ASA [American Society of Anaesthesiologists] grade Ð?Ð?Ð? & Ð?V 3.Pregnant women 4.Patients in whom a written informed consent could not be taken 5.Critically ill patients 6.Patients with known allergy to the above drugs. 7.Patients for emergency upper limb surgeries 8.Patients with coagulopathies, brachial plexus neuropathies, severe bronchopulmonary disease and patients with diabetes. 9.Patients with haemodynamic instability. 10. Neurological deficits involving brachial plexus. 11.Local infection at the injection site.

Design outcomes

Primary

MeasureTime frame
Total duration of the analgesia Timepoint: within 24 hrs post procedure—

Secondary

MeasureTime frame
1)Sensory onset time 2)Duration of sensory block 3)Motor onset time 4)Duration of Motor block 5)Quality of analgesia 6)Adverse events/complicationsTimepoint: within 24 hrs post procedure—

Countries

India

Contacts

Public ContactDr Bharti Lath

Santokba Durlabhji memorial hospital

lath.bharti@gmail.com9829026340

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026